Source link : https://newshealth.biz/health-news/fda-approves-deucravacitinib-as-first-tyk2-inhibitor-for-psa/
In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-approves-deucravacitinib-first-tyk2-inhibitor-psa-2026a100076x?src=rss Author : Publish date : 2026-03-09 17:35:00 Copyright for syndicated content belongs to the linked Source.
The post FDA Approves Deucravacitinib as First TYK2 Inhibitor for PsA first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-09 17:35:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8